Urofollitropin biosimilar (Klarvoyant Biogenics)

尿促卵泡素生物类似药 (Klarvoyant Biogenics)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameUrofollitropin biosimilar (Klarvoyant Biogenics)
Drug Alias Name尿促卵泡素生物仿制药 (Klarvoyant Biogenics)Gamigrourofollitropin follow-on biologic, KlarvoyantGamigro-F
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionFollicle-stimulating hormone receptor agonists
TargetsFollicle-stimulating hormone receptor
Therapy Area/IndicationsInfertility, FemaleInfertility, Male
Global Approved IndicationsInfertility, FemaleInfertility, Male
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2013/07/01
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesKlarvoyant
China Registration ClassN/A

Develop Information

Active CompaniesKlarvoyant
Inactive CompaniesN/A
Active IndicationsInfertility, FemaleInfertility, Male
Inactive IndicationsN/A

Other Information

ATC CodeG03GA04
Related LinksN/A